TBV Dilution and the Earn-Back Period

Introduction

Tangible book value dilution and the earn-back period are the metrics that determine whether a bank deal's pricing is defensible to investors. Every acquisition at a premium above tangible book value creates goodwill and CDI that reduce the acquirer's TBV per share on day one. The earn-back period measures how long it takes for the combined entity's superior earnings power (from cost savings, revenue synergies, and CDI amortization recovery) to rebuild TBV per share to pre-deal levels. For FIG bankers, this metric is the bridge between deal pricing and investor acceptance: a deal with strong EPS accretion but an unacceptable earn-back period will face investor resistance regardless of its strategic merits.

Day-one TBV dilution in a bank merger has three primary drivers, all deducted from the equity base that determines TBV per share.

Goodwill is the largest component. It equals the purchase price minus the fair value of the target's net tangible assets. A bank paying 170% of TBV for a target with $5 billion in tangible equity creates $3.5 billion in goodwill. In a stock-for-stock deal, the acquirer issues new shares (increasing the share count) while simultaneously creating goodwill (reducing tangible equity). The net effect is a decline in TBV per share.

Core deposit intangible adds another layer. CDI, typically valued at 2.5-2.7% of core deposits (2024-2025), is also deducted from tangible equity. A target with $40 billion in core deposits generates approximately $1 billion in CDI, adding to the day-one TBV hit.

Other intangibles (customer relationships, technology, trade names) may also be identified under purchase accounting, further reducing TBV. Fair value marks on assets and liabilities can partially offset these deductions if the target's assets are marked up.

TBV Dilution

TBV dilution is the percentage decline in the acquirer's tangible book value per share on the day a deal closes. It is calculated as: (Pro Forma TBV Per Share - Acquirer Standalone TBV Per Share) / Acquirer Standalone TBV Per Share. The pro forma TBV equals the combined tangible equity of both entities minus all intangibles created in the transaction (goodwill, CDI, other identifiable intangibles), divided by the pro forma share count (acquirer shares plus new shares issued to target shareholders). A deal at 1.0x TBV with no premium creates zero dilution. Every turn above 1.0x creates progressively more dilution because the incremental goodwill exceeds the incremental tangible equity acquired.

The Simple Method

The simple method divides the day-one TBV dilution by the annual TBV accretion (the incremental earnings per share from cost savings and target earnings that exceed what the acquirer would have earned standalone).

This method assumes that the annual earnings benefit phases in immediately at its full run-rate, which overstates the speed of recovery in deals where cost savings ramp over 2-3 years. It is useful for quick screening but lacks precision for detailed analysis.

The Crossover Method

The crossover method is more rigorous. It projects two TBV per share trajectories: the acquirer's standalone path (TBV growing from retained earnings and organic business) and the pro forma combined path (TBV recovering from the day-one dilution through superior combined earnings). The earn-back period is the point where the pro forma trajectory crosses above the standalone trajectory.

The 2024-2025 deal cycle demonstrates the range of TBV dilution and earn-back outcomes.

Fifth Third-Comerica represents the rare case of zero day-one TBV dilution despite a 1.75x P/TBV acquisition. This was achievable because the deal was structured as all-stock with a moderate premium (20% to VWAP), Comerica's profitability was strong enough that the earnings contribution offset the intangible creation, and the exchange ratio was calibrated to minimize the TBV hit. The deal also projected 5% TBV per share accretion excluding one-time charges, meaning the combined entity's TBV actually exceeds what either would have achieved alone.

SouthState-Independent shows a more typical profile: 9.6% TBV dilution with a projected 2-year earn-back. The market accepted the dilution because the earn-back was aggressive (well under the 3-year threshold investors prefer) and the 27% EPS accretion demonstrated strong earnings power from the combination.

CDI amortization plays a dual role in the earn-back calculation. On one hand, CDI amortization reduces GAAP earnings, slowing the accumulation of retained earnings that rebuilds TBV. On the other hand, CDI is a finite-lived intangible that declines each year through amortization, which means the intangible deduction from tangible equity shrinks progressively.

In a deal with $500 million in CDI amortized on an accelerated basis over 10 years, year-one amortization might be $80 million (reducing GAAP earnings) but also reducing the CDI balance from $500 million to $420 million (increasing tangible equity by $80 million). The net effect on TBV per share is positive: tangible equity rises because the intangible deduction shrinks, even though GAAP earnings take a hit.

This mechanism is why CDI-heavy deals can have shorter earn-back periods than the simple method suggests: CDI amortization directly rebuilds tangible equity while goodwill sits on the balance sheet indefinitely (unless impaired). Deals with high CDI relative to total intangibles tend to have faster earn-backs than deals dominated by goodwill.

The market standard for acceptable TBV earn-back has evolved over time, but the current consensus falls in a clear range.

Earn-back scrutiny intensifies with deal premium. A deal at 1.5x TBV with a 3.5-year earn-back faces less resistance than a deal at 2.0x TBV with the same earn-back, because the higher premium implies more goodwill creation and a larger bet on synergy execution. Merger-of-equals structures (like Pinnacle-Synovus) naturally produce shorter earn-backs because the absence of a control premium minimizes goodwill creation.

TBV dilution and earn-back analysis sits alongside EPS accretion/dilution and pro forma capital analysis as the three quantitative tests that determine whether a bank deal is defensible. Together, these metrics form the analytical backbone of every bank M&A transaction that FIG bankers advise on.